For most people, a coronary artery calcium (CAC) score does not go down once it has risen. Calcium deposits in the coronary arteries tend to increase over time, typically by about 20 to 25 percent per year, and the most widely used treatments for heart disease, including statins, actually accelerate the number on the scan. But that fact alone is misleading, because the score itself may not be the most important thing to track. Emerging evidence suggests that what matters more than whether the calcium goes away is what kind of calcium you have and how fast it is accumulating.
Why the Number Almost Always Goes Up
Coronary artery calcium is measured using the Agatston score, a number derived from a CT scan that reflects how much calcified plaque sits in your coronary arteries. A score of zero means no detectable calcium. Scores above 100 are considered moderate, and scores above 300 or so indicate extensive disease. Once you have calcium in those arteries, it rarely disappears. The biological process that deposits it is not easily reversed: smooth muscle cells in artery walls undergo changes that make them behave more like bone-forming cells, actively laying down mineral. Driving that process backward is, at best, extremely difficult with current medicine.
Several large studies confirm this trajectory. The typical annual increase in CAC score sits in that 20 to 25 percent range regardless of treatment, and no widely available medication has been shown to reliably bring the number down in large populations.1Journal of Cardiology & Current Research. Reversing coronary artery calcium using a functional medicine protocol For people who see their score climb between two scans, this can feel alarming. But the climb needs context, because the treatments that raise the calcium score are often the same ones reducing heart attack risk.
The Statin Paradox
Statins are the cornerstone of cardiovascular prevention, and they unambiguously reduce heart attacks and strokes. Yet statins consistently increase CAC scores. A study using intravascular ultrasound found that both high-intensity and low-intensity statin therapy led to significant increases in calcium within coronary plaques compared to no statin use. The researchers concluded that, independent of their ability to shrink overall plaque, statins actively promote calcification of atherosclerotic lesions.2PubMed. Impact of statins on serial coronary calcification during atheroma progression and regression
This sounds contradictory until you understand what the statins are doing to the plaque itself. Atherosclerotic plaques come in different forms. The dangerous ones tend to be soft, lipid-rich, and covered by a thin cap that can rupture and trigger a heart attack. When statins shrink the soft, fatty core of a plaque, they also appear to transform what remains into denser, more heavily calcified tissue. Think of it as turning a soft, fragile shell into something more like concrete: harder to crack open. More recent imaging studies using coronary CT angiography support this interpretation, showing that statins reduce high-risk plaque volumes while shifting plaque composition toward denser calcium without necessarily increasing total calcified plaque volume.3JAMA. Effects of Combining Coronary Calcium Score With Treatment on Plaque Progression in Familial Coronary Artery Disease: A Randomized Clinical Trial
So your CAC score may go up on statins, but the type of calcium you are accumulating could actually be a sign that your plaques are stabilizing. That distinction gets lost when someone fixates on the headline number.
Calcium Density Versus Calcium Volume
This is where the science gets genuinely interesting and where a lot of the public conversation about calcium scores misses the point. The standard Agatston score lumps together the total amount of calcium in your arteries without distinguishing between large patches of low-density calcium and smaller, extremely dense deposits. But those two situations carry very different risks.
Data from the Multi-Ethnic Study of Atherosclerosis (MESA), one of the largest and longest-running cardiovascular cohort studies, found that while higher calcium volume was associated with more heart disease events, higher calcium density was independently associated with lower risk. Each standard-deviation increase in calcium density was linked to roughly a 28 percent lower risk of coronary heart disease and about a 25 percent lower risk of overall cardiovascular disease.4PubMed. Coronary Artery Calcium Volume and Density: Potential Interactions and Overall Predictive Value: The Multi-Ethnic Study of Atherosclerosis An earlier analysis from the same cohort put the protective association of density at a hazard ratio of 0.73 for coronary events and 0.71 for cardiovascular events per standard-deviation increase.5PubMed Central. Calcium Density of Coronary Artery Plaque and Risk of Incident Cardiovascular Events
In other words, dense calcium appears to be a marker of stable, healed plaque. If your score goes up because soft plaques are being replaced with dense calcium, that may represent your body (and your medication) successfully walling off dangerous lesions. The Agatston score, however, was not designed to capture this distinction, which is one reason researchers have been pushing for more nuanced calcium reporting.
What Lifestyle Changes Actually Accomplish
If statins cannot bring the score down, can diet and exercise do it? The honest answer is that healthy habits probably will not reverse an existing calcium score either, but they can meaningfully slow how fast it climbs, and that matters a great deal.
The MESA study tracked thousands of adults over an average of about 7.6 years and assigned each person a lifestyle score based on four factors: regular exercise, a healthy diet, not smoking, and maintaining a healthy weight. People who hit all four healthy benchmarks saw their calcium scores progress roughly 11 points per year slower than those with the worst lifestyle profiles. Even hitting just one or two of these targets provided a measurable benefit. The combination was also associated with lower rates of new calcium appearing in previously clean arteries and with lower all-cause mortality.6PubMed Central. Low-Risk Lifestyle, Coronary Calcium, Cardiovascular Events, and Mortality: Results From MESA
Slowing progression by 11 points a year may not sound dramatic, but over a decade or two, the difference between aggressive and slow calcium accumulation can be the difference between a moderate-risk profile and a high-risk one. And crucially, this lifestyle benefit comes on top of medication, not instead of it.
Small Studies Suggesting Actual Regression
There are a handful of reports showing actual decreases in calcium scores, but they come with heavy caveats. One open-label study of 45 patients with low initial CAC scores (50 or below) used an aggressive combination approach: statin therapy, niacin, omega-3 fatty acids, vitamin D supplementation, and a therapeutic-lifestyle-change diet, all aimed at hitting specific lipid targets. Of those 45 patients, 21 showed a decrease in their calcium score, with reductions ranging up to 64 percent. Another 21 showed slowed progression, and only 3 continued to progress rapidly.7The FASEB Journal. Progression and Regression of Coronary Calcium Score
These results are intriguing, but they are far from definitive. The study was small, uncontrolled, and limited to people who started with very low scores, meaning there was barely any calcium to begin with. Whether the same approach would work for someone with a score of 300 or 500 remains unknown. And at least some of those decreases may reflect measurement variability rather than genuine biological regression. Still, the findings suggest that at the very early stages of calcification, a multi-pronged treatment plan might occasionally produce a lower number on a follow-up scan.
PCSK9 Inhibitors and Newer Drug Approaches
PCSK9 inhibitors are a newer class of cholesterol-lowering drugs that work differently from statins. The question of whether they affect calcium scores differently has attracted real research interest. One study comparing alirocumab (a PCSK9 inhibitor) to standard statin therapy found that statin-treated patients had a median CAC score increase of about 10.6 percent, while alirocumab-treated patients had a much smaller increase of about 2.9 percent. The difference was statistically significant.8PubMed Central. Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease
A separate study using coronary CT angiography to evaluate PCSK9 inhibitor therapy over one year found that while LDL cholesterol dropped substantially (from about 148 to 66 mg/dL), there was no significant change in calcified plaque volume, non-calcified plaque volume, or total plaque volume.9Journal of Thoracic Imaging. Serial Changes in Coronary Plaque Formation Using CT Angiography in Patients Undergoing PCSK9-Inhibitor Therapy With 1-year Follow-up So PCSK9 inhibitors seem to slow calcium progression more than statins do, but they do not reverse it either. Whether the slower progression translates into better outcomes specifically because of calcium effects, rather than just overall LDL reduction, is still being studied.
Vitamin K2 and the Calcium-Routing Theory
Vitamin K2 has attracted a following among people hoping to redirect calcium away from arteries and into bones. The biological rationale has some backing: vitamin K2 activates a protein called matrix GLA protein (MGP), which inhibits calcium from depositing in artery walls. When vitamin K is deficient, MGP stays inactive, and the process of removing or preventing arterial calcium deposits is impaired.10PubMed Central. Proper Calcium Use: Vitamin K2 as a Promoter of Bone and Cardiovascular Health
The theory is plausible and the basic biology checks out: people with lower vitamin K status do tend to have more arterial calcification. But the leap from “vitamin K2 activates a protective protein” to “supplementing K2 will lower your calcium score” is one that clinical trials have not yet firmly established in large populations. Some observational studies show associations between higher K2 intake and lower cardiovascular risk, but high-quality randomized trials specifically showing CAC score reduction from K2 supplementation remain thin on the ground. It is reasonable to ensure you are not deficient in vitamin K2, especially if you take warfarin (which blocks vitamin K activity), but counting on it to erase existing coronary calcium goes beyond what the evidence currently supports.
The Exercise Paradox in Athletes
People who exercise intensely and consistently might expect to have pristine coronary arteries. Many do. But a surprising pattern has emerged in research on lifelong endurance athletes, particularly older men: they tend to have higher CAC scores than sedentary peers of the same age.11Heart. Potential mechanisms linking high-volume exercise with coronary artery calcification The underlying mechanisms are still debated. One theory involves repeated hemodynamic stress on artery walls; another invokes exercise-related inflammation and repair cycles.
What makes this less alarming than it sounds is the composition of the plaque. Coronary plaque in athletes tends to be calcified rather than soft, meaning it leans toward the stable, dense variety that carries less risk.12PubMed Central. Coronary Plaque in Athletes This fits the broader theme: a higher CAC score with dense, stable calcium is a different clinical story than the same score made up of vulnerable, lipid-rich plaques. An athlete with a CAC score of 150, nearly all dense calcium, is not in the same risk category as a sedentary smoker with a score of 150 featuring soft plaque throughout. Standard scoring does not capture this, which is why athletes who get calcium scans sometimes receive misleading risk assessments.
Men Versus Women and the Timeline of Calcification
Calcium scores do not progress equally in men and women. A large Korean registry study found that at five years, roughly 47 percent of men had experienced meaningful CAC progression compared to about 30 percent of women. Male sex was an independent predictor of faster calcium progression, particularly in people at low cardiovascular risk. In the highest-risk groups, the gap between sexes narrowed considerably.13PubMed Central. Sex differences in coronary artery calcium progression: The Korea Initiatives on Coronary Artery Calcification (KOICA) registry
The composition of progressing plaque also differs. A study examining CT angiography over time found that while total plaque volume progressed at similar rates in men and women after adjusting for baseline differences, women tended to develop more calcified plaque and less non-calcified plaque, and were less likely to develop the high-risk plaque features associated with heart attacks.14PubMed. Sex Differences in Compositional Plaque Volume Progression in Patients With Coronary Artery Disease Women also showed roughly a nine-year delay in developing plaque compared to men, consistent with the well-known later onset of coronary disease in women. The practical implication is that the same CAC score at the same age may mean somewhat different things depending on sex.
Dietary Calcium and an Unexpected Wrinkle
A common question for people worried about arterial calcium is whether the calcium in their diet or supplements is contributing to the problem. The answer is counterintuitive. A 10-year follow-up from the MESA cohort found that high total calcium intake from food was actually associated with a decreased risk of developing coronary artery calcium in the first place. But calcium supplements told a different story: supplement use was associated with an increased risk of new calcification appearing.15PubMed Central. Calcium Intake From Diet and Supplements and the Risk of Coronary Artery Calcification and its Progression Among Older Adults: 10-Year Follow-up of the Multi-Ethnic Study of Atherosclerosis (MESA)
The mechanism behind this split is not fully settled, but one theory involves the spike in blood calcium levels that follows a supplement pill versus the slow, steady absorption from food. A bolus of supplemental calcium may transiently raise serum levels enough to promote deposition in artery walls, while dietary calcium absorbed alongside other nutrients does not produce the same spike. This does not mean you should stop calcium supplements if your doctor has prescribed them for bone health. It does mean the decision deserves a conversation about your cardiovascular risk profile rather than a blanket assumption that more calcium is always better.
When Kidney Disease Changes the Rules
Everything discussed so far assumes a functioning kidney. In people with chronic kidney disease (CKD), the calcification picture changes dramatically. CKD patients develop more intense and widespread calcification, and critically, they develop it not just in the inner lining of arteries (the intima, where atherosclerotic plaque forms) but also in the muscular middle layer (the media). This medial calcification is driven by different mechanisms involving disordered mineral metabolism, elevated phosphate levels, and impaired vitamin D processing.16PubMed Central. Vascular Calcification in Chronic Kidney Disease: Distinct Features of Pathogenesis and Clinical Implication
Medial calcification stiffens arteries rather than narrowing them, producing a different set of cardiovascular risks than traditional atherosclerosis. For CKD patients, a calcium score must be interpreted entirely differently than for someone with healthy kidneys, and the strategies for managing it (phosphate binders, specialized vitamin D analogs, avoiding calcium-based supplements) diverge substantially from the general-population playbook. If you have CKD and a high calcium score, the conversation with your nephrologist is more relevant than the standard cardiology framework.
What a Zero Score Means for the Long Run
While this article focuses on reversing a score that has already risen, it is worth noting just how powerful a zero score is as a prognostic tool. Among adults 55 and younger in the MESA cohort, a CAC score of zero predicted very low cardiovascular event rates, about 4 percent at 15 years, over a median follow-up of 16 years. The prognosis was especially favorable for nonsmokers.17PubMed Central. Long-Term Prognostic Implications and Role of Further Testing in Adults Aged ≤55 Years With a Coronary Calcium Score of Zero (from the Multi-Ethnic Study of Atherosclerosis) A separate study in South Asian patients, a population at elevated cardiovascular risk, found that even among symptomatic individuals, a zero score still carried a good long-term prognosis regardless of underlying coronary artery disease severity.18PubMed Central. Prognosis of Zero Coronary Artery Calcium Score in Symptomatic Patients of South Asian Descent – an Experience from a Tertiary Care Center in Pakistan
The practical implication is that if your score is currently zero, the goal is not reversal but preservation. Every year you maintain a zero score is a year of very low cardiovascular risk. And that is where the lifestyle factors, exercise, diet, not smoking, maintaining a healthy weight, earn their keep most clearly.
Better Imaging on the Horizon
Part of the frustration with tracking calcium scores over time is the bluntness of the tool. The Agatston score was developed in the 1990s and treats all calcium as equal. Newer imaging technology may soon change what clinicians can see and measure. Photon-counting CT, a next-generation scanning approach, offers improved spatial and contrast resolution and the ability to discriminate between different tissue compositions more precisely. It can evaluate coronary plaques and calcium even in complex cases with severe calcification that would be difficult to assess with conventional CT.19PubMed. Photon-Counting Computed Tomography in Cardiac Imaging
If photon-counting CT or similar technologies become standard for calcium scoring, the entire conversation about reversal may shift. Instead of asking whether the total number went down, patients and doctors may be able to ask whether the composition of existing calcium is improving, whether density is increasing, and whether soft plaque is being replaced by stable mineral. That would make the question of “reversing” the score less relevant and the question of plaque quality far more central to clinical decision-making.